- UHRA Home
- Browsing by Author
Browsing by Author "Wilcox, Mark H."
Now showing items 1-13 of 13
-
Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model
Baines, Simon D.; O'Connor, Rachael; Saxton, Katie; Freeman, Jane; Wilcox, Mark H. (2008)To compare the efficacy of oritavancin and vancomycin in the treatment of Clostridium difficile infection (CDI) using an in vitro human gut model. -
Comparison of planktonic and biofilm-associated communities of Clostridium difficile and indigenous gut microbiota in a triple-stage chemostat gut model
Crowther, Grace S.; Chilton, Caroline H.; Todhunter, Sharie L.; Nicholson, Scott; Freeman, Jane; Baines, Simon D.; Wilcox, Mark H. (2014-04-30)BACKGROUND: Biofilms are characteristic of some chronic or recurrent infections and this mode of growth tends to reduce treatment efficacy. Clostridium difficile infection (CDI) is associated with a high rate of recurrent ... -
Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection
Freeman, Jane; Baines, Simon D.; Jabes, Daniela; Wilcox, Mark H. (2005-09)Treatment of Clostridium difficile infection (CDI) is limited primarily to either metronidazole or vancomycin. We compared vancomycin and a novel glycolipodepsipeptide, ramoplanin, in both hamster and in vitro gut models ... -
Development and validation of a chemostat gut model to study both planktonic and biofilm modes of growth of Clostridium difficile and human microbiota
Crowther, Grace S.; Chilton, Caroline H.; Todhunter, Sharie L.; Nicholson, Scott; Freeman, Jane; Baines, Simon D.; Wilcox, Mark H. (2014-02-06)The human gastrointestinal tract harbours a complex microbial community which exist in planktonic and sessile form. The degree to which composition and function of faecal and mucosal microbiota differ remains unclear. We ... -
Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model
Freeman, Jane; Baines, Simon D.; Saxton, Katie; Wilcox, Mark H. (2007)We compared the behaviour of Clostridium difficile PCR ribotypes 001 and 027 in a human gut model, and compared the responses to metronidazole exposure. -
Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model
Baines, Simon D.; Freeman, Jane; Wilcox, Mark H. (2005-06)Clostridium difficile infection (CDI) is a major cause of morbidity in the nosocomial environment. Antimicrobial agents such as the third-generation cephalosporins, lincosamides and aminopenicillins are well known for their ... -
Evaluation of antimicrobial activity of ceftaroline against Clostridium difficile and propensity to induce C. difficile infection in an in vitro human gut model
Baines, Simon D.; Chilton, Caroline H.; Crowther, Grace S.; Todhunter, Sharie L.; Freeman, Jane; Wilcox, Mark H. (2013)OBJECTIVES: To examine the effects of exposure to ceftaroline or ceftriaxone on the epidemic Clostridium difficile strain PCR ribotype 027 and the indigenous gut microflora in an in vitro human gut model. Additionally, the ... -
In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin
O'Connor, Rachael; Baines, Simon D.; Freeman, Jane; Wilcox, Mark H. (2008)Clostridium difficile infection is a nosocomial disease of increasing importance. First-line treatment is limited to metronidazole or vancomycin. Oritavancin is a lipoglycopeptide with activity against Gram-positive bacteria, ... -
Mixed infection by Clostridium difficile in an in vitro model of the human gut
Baines, Simon D.; Crowther, Grace S.; Todhunter, Sharie L.; Freeman, Jane; Chilton, Caroline H.; Fawley, Warren N.; Wilcox, Mark H. (2013)OBJECTIVES: Clostridium difficile infection (CDI) is still a major clinical challenge. Previous studies have demonstrated multiple distinct C. difficile strains in the faeces of patients with CDI; yet whether true mixed ... -
Non-Toxigenic Clostridioides difficile Strain E4 (NTCD-E4) Prevents Establishment of Primary C. difficile Infection by Epidemic PCR Ribotype 027 in an In Vitro Human Gut Model
Etifa, Perezimor; Rodríguez, César; Harmanus, Céline; Sanders, Ingrid M. J. G.; Sidorov, Igor A.; Mohammed, Olufunmilayo A.; Savage, Emily; Timms, Andrew R.; Freeman, Jane; Smits, Wiep Klaas; Wilcox, Mark H.; Baines, Simon D. (2023-02-22)Clostridioides difficile infection (CDI) remains a significant healthcare burden. Non-toxigenic C. difficile (NTCD) strains have shown a benefit in preventing porcine enteritis and in human recurrent CDI. In this study, ... -
Short-term genome stability of serial Clostridium difficile ribotype 027 isolates in an experimental gut model and recurrent human disease
Eyre, David W.; Walker, A. Sarah; Freeman, Jane; Baines, Simon D.; Fawley, Warren N.; Chilton, Caroline H.; Griffiths, David; Vaughan, Alison; Crook, Derrick W.; Peto, Tim E. A.; Wilcox, Mark H. (2013-05-15)Clostridium difficile whole genome sequencing has the potential to identify related isolates, even among otherwise indistinguishable strains, but interpretation depends on understanding genomic variation within isolates ... -
Surveillance for resistance to metronidazole and vancomycin in genotypically distinct and UK epidemic Clostridium difficile isolates in a large teaching hospital
Freeman, Jane; Stott, Joanna; Baines, Simon D.; Fawley, Warren N.; Wilcox, Mark H. (2005-11) -
Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model
Baines, Simon D.; Saxton, Katie; Freeman, Jane; Wilcox, Mark H. (2006)Data on the risk of Clostridium difficile infection (CDI) associated with specific antibiotics are difficult to obtain because of confounding clinical factors. It is particularly important to evaluate the propensity of new ...